Board Committees

Craig Johnson has more than 30 years of experience serving in senior financial management roles and governing corporations, primarily in the biotechnology industry. He has served as a director of Heron Therapeutics, Inc. since 2014 and Odonate, Inc. since 2017.

Mr. Johnson previously served as a director of Mirati Therapeutics, Inc. from 2013 until its acquisition by Bristol Myers Squibb in 2024, and as a director of La Jolla Pharmaceutical Company from 2013 until its acquisition by Innoviva, Inc. in 2022. He served as a director of Decipher Biosciences, Inc. from 2015 to 2018, as director of Adamis Pharmaceuticals Corporation from 2011 to 2014, and as a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012.

Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. From 1994 to 2004, he held various positions at MitoKor, Inc., concluding his service as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson practiced as a Certified Public Accountant with Price Waterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

Since 2020, Jeffrey A. Bailey has served as Chairman of the Board at Tekla Capital Management, a registered investment adviser, based in Boston, with four, multi-billion dollar, closed-end funds that predominately invest in the securities of public and private healthcare companies. He has also been Chairman of the Board of Aileron Therapeutics since 2017. 

Mr. Bailey has significant pharmaceutical and biotech leadership experience, with expertise in supply chain, commercial, finance, business development, and product development. He has deep experience managing shareholder expectations and company objectives to achieve a successful outcome. Mr. Bailey has held multiple President, Chief Executive Officer, and leadership roles at biotech and pharmaceutical companies where he oversaw improvements in strategic operations and led the organizations through successful acquisitions, including BioDelivery Sciences (2020-2022), Illuminoss (2018-2020), Neurovance (2015-2017), Lantheus Medical Imaging (2013-2015), and Fougera Pharmaceuticals (2011-2012).

From 2010 to 2011, Mr. Bailey served as Chief Commercial Officer at King Pharmaceuticals, where he led more than 750 employees delivering more than $1.5 billion in annual sales. From 2008 to 2010, Mr. Bailey was President and General Manager at Novartis, where he led a 1000-member primary care and specialty pharma team delivering more than $825 million in sales. 

Mr. Bailey began his career in 1984 at the Johnson & Johnson Family of Companies where he earned successive leadership roles over the course of 20 years. He holds a degree in Business Administration from Rutgers University in New Brunswick, NJ.

Dr. Daniel G. Billen has over 40 years of experience in the commercialization of pharmaceutical and biotech products both in Europe and North America. He started with Janssen Pharmaceuticals, first in its Belgian headquarters in cardiovascular global marketing and later launching multiple products in the Canadian market. Dr. Billen joined Amgen as the first General Manager leading their Canadian operations. He moved to Amgen’s headquarters in California to lead the U.S. Commercial Operations and later served as Vice President/General Manager of the combined Nephrology and Inflammation business and Vice President of Global Commercial Initiatives with a focus on the evolving U.S. payer landscape.

Dr. Billen received his Ph.D. in chemistry from the University of Louvain in Belgium.

Kevin Tang is the President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Kevin founded Concentra Biosciences, LLC in 2023 and has since served as its Chairman. In 2013, he founded Odonate, Inc. and has since served as its Chairman. From 2014 through its acquisition by Innoviva, Inc. in 2022, Kevin was Chairman of La Jolla Pharmaceutical Company. He co-founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Kevin was a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Kevin served as a director of Trimeris, Inc. From 1993 to 2001, he was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm’s Life Sciences research group. Kevin received a B.S. degree from Duke University.

Since 2020, Jeffrey A. Bailey has served as Chairman of the Board at Tekla Capital Management, a registered investment adviser, based in Boston, with four, multi-billion dollar, closed-end funds that predominately invest in the securities of public and private healthcare companies. He has also been Chairman of the Board of Aileron Therapeutics since 2017. 

Mr. Bailey has significant pharmaceutical and biotech leadership experience, with expertise in supply chain, commercial, finance, business development, and product development. He has deep experience managing shareholder expectations and company objectives to achieve a successful outcome. Mr. Bailey has held multiple President, Chief Executive Officer, and leadership roles at biotech and pharmaceutical companies where he oversaw improvements in strategic operations and led the organizations through successful acquisitions, including BioDelivery Sciences (2020-2022), Illuminoss (2018-2020), Neurovance (2015-2017), Lantheus Medical Imaging (2013-2015), and Fougera Pharmaceuticals (2011-2012).

From 2010 to 2011, Mr. Bailey served as Chief Commercial Officer at King Pharmaceuticals, where he led more than 750 employees delivering more than $1.5 billion in annual sales. From 2008 to 2010, Mr. Bailey was President and General Manager at Novartis, where he led a 1000-member primary care and specialty pharma team delivering more than $825 million in sales. 

Mr. Bailey began his career in 1984 at the Johnson & Johnson Family of Companies where he earned successive leadership roles over the course of 20 years. He holds a degree in Business Administration from Rutgers University in New Brunswick, NJ.

Dr. Daniel G. Billen has over 40 years of experience in the commercialization of pharmaceutical and biotech products both in Europe and North America. He started with Janssen Pharmaceuticals, first in its Belgian headquarters in cardiovascular global marketing and later launching multiple products in the Canadian market. Dr. Billen joined Amgen as the first General Manager leading their Canadian operations. He moved to Amgen’s headquarters in California to lead the U.S. Commercial Operations and later served as Vice President/General Manager of the combined Nephrology and Inflammation business and Vice President of Global Commercial Initiatives with a focus on the evolving U.S. payer landscape.

Dr. Billen received his Ph.D. in chemistry from the University of Louvain in Belgium.

Dr. Brinda Balakrishnan currently serves as Senior Vice President, Chief Business Development Officer at BioMarin Pharmaceutical Inc., where she leads initiatives on corporate strategy, mergers/acquisitions/licensing, and alliance management. Dr. Balakrishnan’s prior experience includes co-founding a rare disease, ophthalmic biotech company focused on Stargardt Disease. She has also served biopharma clients as a consultant with McKinsey & Company and led various deals in business development at Genzyme.

Dr. Balakrishnan earned a Ph.D. in biomedical engineering and chemical engineering and a B.S. in chemical engineering from the Massachusetts Institute of Technology. She earned her M.D. from Harvard Medical School and conducted her medical training in internal medicine at Beth Israel Deaconess Medical Center.

Craig Johnson has more than 30 years of experience serving in senior financial management roles and governing corporations, primarily in the biotechnology industry. He has served as a director of Heron Therapeutics, Inc. since 2014 and Odonate, Inc. since 2017.

Mr. Johnson previously served as a director of Mirati Therapeutics, Inc. from 2013 until its acquisition by Bristol Myers Squibb in 2024, and as a director of La Jolla Pharmaceutical Company from 2013 until its acquisition by Innoviva, Inc. in 2022. He served as a director of Decipher Biosciences, Inc. from 2015 to 2018, as director of Adamis Pharmaceuticals Corporation from 2011 to 2014, and as a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012.

Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. From 1994 to 2004, he held various positions at MitoKor, Inc., concluding his service as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson practiced as a Certified Public Accountant with Price Waterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

Mr. R. Hector MacKay-Dunn has over 30 years of practice experience providing legal advice to high-growth public and private companies over a broad range of industry sectors including life sciences and health and technology. He has also advised on corporate domestic and cross-border public and private securities offerings, mergers, acquisitions and international partnering and licensing transactions, and boards of directors and independent board committees on corporate governance matters. Mr. MacKay-Dunn has received numerous awards and recognition from the Canadian legal community.

Mr. MacKay-Dunn has served as a board member or officer with Aspreva Pharmaceuticals Corporation, Arbutus Biopharma Corp., XBiotech Inc. and QLT Inc., the BC (British Columbia) Tech Association, Lifesciences British Columbia, Genome British Columbia, and Tennis Canada.

Mr. MacKay-Dunn earned a J.D. and B.A. from the University of British Columbia.

Kevin Tang is the President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Kevin founded Concentra Biosciences, LLC in 2023 and has since served as its Chairman. In 2013, he founded Odonate, Inc. and has since served as its Chairman. From 2014 through its acquisition by Innoviva, Inc. in 2022, Kevin was Chairman of La Jolla Pharmaceutical Company. He co-founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Kevin was a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Kevin served as a director of Trimeris, Inc. From 1993 to 2001, he was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm’s Life Sciences research group. Kevin received a B.S. degree from Duke University.

Kevin Tang is the President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Kevin founded Concentra Biosciences, LLC in 2023 and has since served as its Chairman. In 2013, he founded Odonate, Inc. and has since served as its Chairman. From 2014 through its acquisition by Innoviva, Inc. in 2022, Kevin was Chairman of La Jolla Pharmaceutical Company. He co-founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Kevin was a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Kevin served as a director of Trimeris, Inc. From 1993 to 2001, he was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm’s Life Sciences research group. Kevin received a B.S. degree from Duke University.

Since 2020, Jeffrey A. Bailey has served as Chairman of the Board at Tekla Capital Management, a registered investment adviser, based in Boston, with four, multi-billion dollar, closed-end funds that predominately invest in the securities of public and private healthcare companies. He has also been Chairman of the Board of Aileron Therapeutics since 2017. 

Mr. Bailey has significant pharmaceutical and biotech leadership experience, with expertise in supply chain, commercial, finance, business development, and product development. He has deep experience managing shareholder expectations and company objectives to achieve a successful outcome. Mr. Bailey has held multiple President, Chief Executive Officer, and leadership roles at biotech and pharmaceutical companies where he oversaw improvements in strategic operations and led the organizations through successful acquisitions, including BioDelivery Sciences (2020-2022), Illuminoss (2018-2020), Neurovance (2015-2017), Lantheus Medical Imaging (2013-2015), and Fougera Pharmaceuticals (2011-2012).

From 2010 to 2011, Mr. Bailey served as Chief Commercial Officer at King Pharmaceuticals, where he led more than 750 employees delivering more than $1.5 billion in annual sales. From 2008 to 2010, Mr. Bailey was President and General Manager at Novartis, where he led a 1000-member primary care and specialty pharma team delivering more than $825 million in sales. 

Mr. Bailey began his career in 1984 at the Johnson & Johnson Family of Companies where he earned successive leadership roles over the course of 20 years. He holds a degree in Business Administration from Rutgers University in New Brunswick, NJ.

Craig Johnson has more than 30 years of experience serving in senior financial management roles and governing corporations, primarily in the biotechnology industry. He has served as a director of Heron Therapeutics, Inc. since 2014 and Odonate, Inc. since 2017.

Mr. Johnson previously served as a director of Mirati Therapeutics, Inc. from 2013 until its acquisition by Bristol Myers Squibb in 2024, and as a director of La Jolla Pharmaceutical Company from 2013 until its acquisition by Innoviva, Inc. in 2022. He served as a director of Decipher Biosciences, Inc. from 2015 to 2018, as director of Adamis Pharmaceuticals Corporation from 2011 to 2014, and as a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012.

Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. From 1994 to 2004, he held various positions at MitoKor, Inc., concluding his service as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson practiced as a Certified Public Accountant with Price Waterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

Mr. R. Hector MacKay-Dunn has over 30 years of practice experience providing legal advice to high-growth public and private companies over a broad range of industry sectors including life sciences and health and technology. He has also advised on corporate domestic and cross-border public and private securities offerings, mergers, acquisitions and international partnering and licensing transactions, and boards of directors and independent board committees on corporate governance matters. Mr. MacKay-Dunn has received numerous awards and recognition from the Canadian legal community.

Mr. MacKay-Dunn has served as a board member or officer with Aspreva Pharmaceuticals Corporation, Arbutus Biopharma Corp., XBiotech Inc. and QLT Inc., the BC (British Columbia) Tech Association, Lifesciences British Columbia, Genome British Columbia, and Tennis Canada.

Mr. MacKay-Dunn earned a J.D. and B.A. from the University of British Columbia.